The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression

Haraldur S. Thorsteinsson, J. Christian Gillin, Christi Ann Patten, Shahrokh Golshan, Laura D. Sutton, Sean Drummond, Camellia P. Clark, John Kelsoe, Mark Rapaport

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

This study examines the effects of transdermal nicotine patches for smoking cessation on depressive and withdrawal symptoms among 38 non-medicated subjects with Major Depressive Disorder. The study was conducted over a 29-day period, which included a 7 day baseline phase, a 14 day treatment phase, and an 8 day placebo phase. During the treatment phase subjects received either active nicotine patches (N = 18) or placebo patches (N = 20) that were administered in a randomized, double-blind fashion. The target quit date (TQD) was day 8. Significantly, more subjects in the placebo group than in the nicotine group resumed smoking following the TQD (50% vs. 22%). There was little evidence for effects of active nicotine patches on measures of mood (HRSD, BDI, POMS) or withdrawal symptoms among subjects that remained abstinent throughout the study (N = 24). Those who resumed smoking had more severe withdrawal symptoms than those who remained abstinent. One patient in the placebo group (n = 20) became more depressed after 2 weeks of abstinence. None of the patients in the nicotine group (n = 18) became more depressed.

Original languageEnglish (US)
Pages (from-to)350-358
Number of pages9
JournalNeuropsychopharmacology
Volume24
Issue number4
DOIs
StatePublished - 2001

Fingerprint

Smoking Cessation
Tobacco Use Cessation Products
Nicotine
Substance Withdrawal Syndrome
Placebos
Depression
Smoking
Major Depressive Disorder
Therapeutics

Keywords

  • Depressive disorder
  • Nicotine
  • Randomized clinical trial
  • Smoking cessation
  • Withdrawal symptoms

ASJC Scopus subject areas

  • Pharmacology

Cite this

The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression. / Thorsteinsson, Haraldur S.; Gillin, J. Christian; Patten, Christi Ann; Golshan, Shahrokh; Sutton, Laura D.; Drummond, Sean; Clark, Camellia P.; Kelsoe, John; Rapaport, Mark.

In: Neuropsychopharmacology, Vol. 24, No. 4, 2001, p. 350-358.

Research output: Contribution to journalArticle

Thorsteinsson, HS, Gillin, JC, Patten, CA, Golshan, S, Sutton, LD, Drummond, S, Clark, CP, Kelsoe, J & Rapaport, M 2001, 'The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression', Neuropsychopharmacology, vol. 24, no. 4, pp. 350-358. https://doi.org/10.1016/S0893-133X(00)00217-7
Thorsteinsson, Haraldur S. ; Gillin, J. Christian ; Patten, Christi Ann ; Golshan, Shahrokh ; Sutton, Laura D. ; Drummond, Sean ; Clark, Camellia P. ; Kelsoe, John ; Rapaport, Mark. / The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression. In: Neuropsychopharmacology. 2001 ; Vol. 24, No. 4. pp. 350-358.
@article{cf0ab58eceea47d581563a57c9f6a163,
title = "The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression",
abstract = "This study examines the effects of transdermal nicotine patches for smoking cessation on depressive and withdrawal symptoms among 38 non-medicated subjects with Major Depressive Disorder. The study was conducted over a 29-day period, which included a 7 day baseline phase, a 14 day treatment phase, and an 8 day placebo phase. During the treatment phase subjects received either active nicotine patches (N = 18) or placebo patches (N = 20) that were administered in a randomized, double-blind fashion. The target quit date (TQD) was day 8. Significantly, more subjects in the placebo group than in the nicotine group resumed smoking following the TQD (50{\%} vs. 22{\%}). There was little evidence for effects of active nicotine patches on measures of mood (HRSD, BDI, POMS) or withdrawal symptoms among subjects that remained abstinent throughout the study (N = 24). Those who resumed smoking had more severe withdrawal symptoms than those who remained abstinent. One patient in the placebo group (n = 20) became more depressed after 2 weeks of abstinence. None of the patients in the nicotine group (n = 18) became more depressed.",
keywords = "Depressive disorder, Nicotine, Randomized clinical trial, Smoking cessation, Withdrawal symptoms",
author = "Thorsteinsson, {Haraldur S.} and Gillin, {J. Christian} and Patten, {Christi Ann} and Shahrokh Golshan and Sutton, {Laura D.} and Sean Drummond and Clark, {Camellia P.} and John Kelsoe and Mark Rapaport",
year = "2001",
doi = "10.1016/S0893-133X(00)00217-7",
language = "English (US)",
volume = "24",
pages = "350--358",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression

AU - Thorsteinsson, Haraldur S.

AU - Gillin, J. Christian

AU - Patten, Christi Ann

AU - Golshan, Shahrokh

AU - Sutton, Laura D.

AU - Drummond, Sean

AU - Clark, Camellia P.

AU - Kelsoe, John

AU - Rapaport, Mark

PY - 2001

Y1 - 2001

N2 - This study examines the effects of transdermal nicotine patches for smoking cessation on depressive and withdrawal symptoms among 38 non-medicated subjects with Major Depressive Disorder. The study was conducted over a 29-day period, which included a 7 day baseline phase, a 14 day treatment phase, and an 8 day placebo phase. During the treatment phase subjects received either active nicotine patches (N = 18) or placebo patches (N = 20) that were administered in a randomized, double-blind fashion. The target quit date (TQD) was day 8. Significantly, more subjects in the placebo group than in the nicotine group resumed smoking following the TQD (50% vs. 22%). There was little evidence for effects of active nicotine patches on measures of mood (HRSD, BDI, POMS) or withdrawal symptoms among subjects that remained abstinent throughout the study (N = 24). Those who resumed smoking had more severe withdrawal symptoms than those who remained abstinent. One patient in the placebo group (n = 20) became more depressed after 2 weeks of abstinence. None of the patients in the nicotine group (n = 18) became more depressed.

AB - This study examines the effects of transdermal nicotine patches for smoking cessation on depressive and withdrawal symptoms among 38 non-medicated subjects with Major Depressive Disorder. The study was conducted over a 29-day period, which included a 7 day baseline phase, a 14 day treatment phase, and an 8 day placebo phase. During the treatment phase subjects received either active nicotine patches (N = 18) or placebo patches (N = 20) that were administered in a randomized, double-blind fashion. The target quit date (TQD) was day 8. Significantly, more subjects in the placebo group than in the nicotine group resumed smoking following the TQD (50% vs. 22%). There was little evidence for effects of active nicotine patches on measures of mood (HRSD, BDI, POMS) or withdrawal symptoms among subjects that remained abstinent throughout the study (N = 24). Those who resumed smoking had more severe withdrawal symptoms than those who remained abstinent. One patient in the placebo group (n = 20) became more depressed after 2 weeks of abstinence. None of the patients in the nicotine group (n = 18) became more depressed.

KW - Depressive disorder

KW - Nicotine

KW - Randomized clinical trial

KW - Smoking cessation

KW - Withdrawal symptoms

UR - http://www.scopus.com/inward/record.url?scp=0035138753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035138753&partnerID=8YFLogxK

U2 - 10.1016/S0893-133X(00)00217-7

DO - 10.1016/S0893-133X(00)00217-7

M3 - Article

C2 - 11182530

AN - SCOPUS:0035138753

VL - 24

SP - 350

EP - 358

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 4

ER -